Pitt Street Research has released an equity valuation report on clinical stage oncology company Prescient Therapeutics (ASX: PTX) that outlines a prosperous and swift path…

Prescient Therapeutics (ASX: PTX) reported encouraging results in several key targeted and cell therapies in its September quarter activities report. The clinical-stage oncology company report…

Prescient Therapeutics (ASX: PTX) has been invited to present clinical data at the prestigious American Society of Hematology (ASH) Annual Meeting in December.

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive Dr Ellen Feigal as a Non-Executive Director of PTX. Dr…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell & Gene Meeting on the Mediterranean, after being invited to present…

Clinical stage oncology company, Prescient Therapeutics (ASX: PTX), has received an expanded Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for its…

Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage assets across CAR-T and targeted cell therapies. The company has…

Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy and radiation. Each poses their own benefits, risks and limitations….